YungShin Global Holding Corp

TW:3705 Taiwan Drug Manufacturers - Specialty & Generic
Market Cap
$425.88 Million
NT$14.09 Billion TWD
Market Cap Rank
#12996 Global
#404 in Taiwan
Share Price
NT$52.90
Change (1 day)
+0.00%
52-Week Range
NT$52.90 - NT$68.80
All Time High
NT$68.80
About

YungShin Global Holding Corporation, through its subsidiaries, invests in, manufactures, and sells medicines, animal drugs, agricultural chemicals, industrial medicines, and cosmetics. It is also involved in the sale of medicine; trade, investment, and other related businesses; import and export trading; and food manufacturing. The company operates in Taiwan, the United States, Mainland China, an… Read more

YungShin Global Holding Corp (3705) - Net Assets

Latest net assets as of September 2025: NT$8.58 Billion TWD

Based on the latest financial reports, YungShin Global Holding Corp (3705) has net assets worth NT$8.58 Billion TWD as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$11.97 Billion) and total liabilities (NT$3.39 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets NT$8.58 Billion
% of Total Assets 71.65%
Annual Growth Rate 3.19%
5-Year Change 51.7%
10-Year Change 61.96%
Growth Volatility 5.64

YungShin Global Holding Corp - Net Assets Trend (2000–2024)

This chart illustrates how YungShin Global Holding Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for YungShin Global Holding Corp (2000–2024)

The table below shows the annual net assets of YungShin Global Holding Corp from 2000 to 2024.

Year Net Assets Change
2024-12-31 NT$9.98 Billion +26.04%
2023-12-31 NT$7.91 Billion +2.75%
2022-12-31 NT$7.70 Billion +13.48%
2021-12-31 NT$6.79 Billion +3.22%
2020-12-31 NT$6.58 Billion +2.45%
2019-12-31 NT$6.42 Billion +3.54%
2018-12-31 NT$6.20 Billion +2.93%
2017-12-31 NT$6.02 Billion +0.11%
2016-12-31 NT$6.02 Billion -2.33%
2015-12-31 NT$6.16 Billion +4.48%
2014-12-31 NT$5.90 Billion +4.48%
2013-12-31 NT$5.64 Billion +0.75%
2012-12-31 NT$5.60 Billion -2.06%
2011-12-31 NT$5.72 Billion +2.69%
2010-12-31 NT$5.57 Billion +3.34%
2009-12-31 NT$5.39 Billion +1.01%
2008-12-31 NT$5.34 Billion +1.12%
2007-12-31 NT$5.28 Billion +4.34%
2006-12-31 NT$5.06 Billion +1.00%
2005-12-31 NT$5.01 Billion 0.00%
2004-12-31 NT$5.01 Billion +4.71%
2003-12-31 NT$4.78 Billion +2.77%
2002-12-31 NT$4.65 Billion -1.84%
2001-12-31 NT$4.74 Billion +0.92%
2000-12-31 NT$4.70 Billion --

Equity Component Analysis

This analysis shows how different components contribute to YungShin Global Holding Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 73.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings NT$1.94 Billion 24.35%
Common Stock NT$2.66 Billion 33.43%
Other Comprehensive Income NT$1.03 Billion 12.93%
Other Components NT$2.33 Billion 29.29%
Total Equity NT$7.97 Billion 100.00%

YungShin Global Holding Corp Competitors by Market Cap

The table below lists competitors of YungShin Global Holding Corp ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in YungShin Global Holding Corp's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 7,342,674,000 to 7,969,631,000, a change of 626,957,000 (8.5%).
  • Net income of 1,168,508,000 contributed positively to equity growth.
  • Dividend payments of 672,883,000 reduced retained earnings.
  • Other comprehensive income increased equity by 186,001,999.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income NT$1.17 Billion +14.66%
Dividends Paid NT$672.88 Million -8.44%
Other Comprehensive Income NT$186.00 Million +2.33%
Other Changes NT$-54.67 Million -0.69%
Total Change NT$- 8.54%

Book Value vs Market Value Analysis

This analysis compares YungShin Global Holding Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.77x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 2.81x to 1.77x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2005-12-31 NT$18.82 NT$52.90 x
2006-12-31 NT$18.98 NT$52.90 x
2008-12-31 NT$19.56 NT$52.90 x
2009-12-31 NT$19.61 NT$52.90 x
2010-12-31 NT$20.29 NT$52.90 x
2011-12-31 NT$20.82 NT$52.90 x
2012-12-31 NT$20.44 NT$52.90 x
2013-12-31 NT$20.47 NT$52.90 x
2014-12-31 NT$21.36 NT$52.90 x
2015-12-31 NT$22.29 NT$52.90 x
2016-12-31 NT$21.85 NT$52.90 x
2017-12-31 NT$22.08 NT$52.90 x
2018-12-31 NT$22.83 NT$52.90 x
2019-12-31 NT$23.46 NT$52.90 x
2020-12-31 NT$24.03 NT$52.90 x
2021-12-31 NT$24.54 NT$52.90 x
2022-12-31 NT$26.87 NT$52.90 x
2023-12-31 NT$27.56 NT$52.90 x
2024-12-31 NT$29.91 NT$52.90 x

Capital Efficiency Dashboard

This dashboard shows how efficiently YungShin Global Holding Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 14.66%
  • The company shows good efficiency in utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 14.55%
  • • Asset Turnover: 0.58x
  • • Equity Multiplier: 1.73x
  • Recent ROE (14.66%) is above the historical average (10.80%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2000 6.36% 10.36% 0.51x 1.21x NT$-166.73 Million
2001 8.32% 12.18% 0.50x 1.36x NT$-77.11 Million
2002 9.73% 14.25% 0.50x 1.37x NT$-12.77 Million
2003 10.45% 15.62% 0.49x 1.37x NT$21.53 Million
2004 14.43% 18.73% 0.56x 1.38x NT$221.56 Million
2005 14.43% 25.71% 0.48x 1.16x NT$221.56 Million
2006 9.31% 15.89% 0.51x 1.15x NT$-35.02 Million
2007 10.81% 14.94% 0.56x 1.29x NT$41.93 Million
2008 2.29% 12.72% 0.15x 1.23x NT$-403.16 Million
2009 10.04% 12.85% 0.61x 1.27x NT$1.97 Million
2010 11.75% 15.33% 0.60x 1.28x NT$94.48 Million
2011 9.99% 12.31% 0.62x 1.32x NT$-476.70K
2012 8.16% 9.45% 0.64x 1.36x NT$-100.10 Million
2013 11.35% 12.23% 0.62x 1.51x NT$73.55 Million
2014 12.65% 12.36% 0.67x 1.53x NT$151.03 Million
2015 15.04% 14.80% 0.65x 1.56x NT$299.34 Million
2016 11.31% 10.63% 0.61x 1.75x NT$75.96 Million
2017 8.74% 7.76% 0.60x 1.87x NT$-74.19 Million
2018 11.54% 9.34% 0.64x 1.93x NT$93.61 Million
2019 11.98% 9.14% 0.66x 1.98x NT$123.59 Million
2020 12.36% 9.79% 0.64x 1.97x NT$151.39 Million
2021 11.27% 9.44% 0.65x 1.84x NT$82.83 Million
2022 11.72% 11.48% 0.62x 1.66x NT$123.05 Million
2023 11.27% 11.77% 0.61x 1.57x NT$93.04 Million
2024 14.66% 14.55% 0.58x 1.73x NT$371.54 Million

Industry Comparison

This section compares YungShin Global Holding Corp's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $4,509,803,556
  • Average return on equity (ROE) among peers: 3.65%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
YungShin Global Holding Corp (3705) NT$8.58 Billion 6.36% 0.40x $292.12 Million
Grape King Bio Ltd (1707) $11.79 Billion 12.28% 0.30x $413.97 Million
Standard Chemical & Pharmaceutical Co Ltd (1720) $8.14 Billion 10.26% 0.37x $160.24 Million
Maywufa Co Ltd (1731) $2.11 Billion 8.22% 0.51x $41.33 Million
Allied Biotech Corporation (1780) $1.17 Billion 8.33% 0.78x $47.92 Million
ScinoPharm Taiwan Ltd (1789) $9.38 Billion 5.16% 0.21x $180.77 Million
GeneFerm Biotechnology Co Ltd (1796) $396.19 Million 1.14% 1.48x $24.30 Million
Easywell Biomedicals Inc. (1799) $696.90 Million -39.00% 0.68x $62.14 Million
LIWANLI Innovation Co Ltd (3054) $799.59 Million 4.48% 0.55x $49.55 Million
TTY Biopharm Co Ltd (4105) $6.11 Billion 22.00% 0.56x $486.74 Million